Latest Safety News

Cynata Therapeutics has completed the 100-day primary evaluation period for its Phase 2 trial of CYP-001 in acute graft versus host disease, with results expected in June 2026. This milestone marks a critical step for the biotech’s lead cell therapy candidate in a condition with few effective treatments.

Boab Metals has received the crucial regulatory green light for its Sorby Hills project, clearing the way for full-scale mining operations and first concentrate production targeted in late 2027.

SRJ Technologies’ subsidiary ACE has landed two advanced inspection contracts worth a combined £235k with a leading global energy supermajor, reinforcing its foothold in offshore asset integrity services.

DGL Group Limited has replaced its ANZ-led financing with a new $120 million facility from ScotPac, extending maturity and enhancing working capital flexibility amid ongoing management restructuring.

Spacetalk Ltd has secured firm commitments to raise approximately $6 million through a two-tranche share placement, alongside appointing Andrew Grover as an independent Non-Executive Director. The capital raise aims to accelerate app development and support growing subscriber demand.

Duratec Limited’s subsidiary has secured a significant multi-million dollar contract to provide plug and abandonment services in Papua New Guinea, marking a strategic expansion in the energy services sector.

Star Minerals has reported robust grade control drilling results at its Tumblegum South Gold Project, confirming excellent continuity and grade of gold mineralisation ahead of final mine planning.

ABx Group’s ALCORE subsidiary has reached a key environmental milestone for its hydrogen fluoride pilot plant in Tasmania, progressing construction and expanding its engineering team ahead of commissioning in late 2026.

Titomic Limited has secured a significant $1.7 million purchase order from the Netherlands’ Royal NLR, reinforcing its foothold in European aerospace and defense additive manufacturing.

Radiopharm Theranostics has initiated dosing in its Phase 1 clinical trial of RAD 402, a novel radiolabelled antibody targeting KLK3 in advanced prostate cancer. Early data from the trial’s initial dose levels are expected in the second half of 2026.

Blue Star Helium has completed Stage 1 of its Galactica Project, tying six wells into the Pinon Canyon facility and initiating spot-priced helium sales as it moves toward continuous operations and long-term contracts.

Javelin Minerals has launched a targeted drilling campaign at its Eureka Gold Project in WA, aiming to extend high-grade gold mineralisation and capitalise on a newly expanded mining lease. The company is poised for near-term production under a joint venture with MEGA Resources.